Monoclonal Antibody Treatment (Regen-COV)
If you test positive for COVID-19, know that there are treatments available. Innovative Care offers monoclonal antibody treatment to COVID positive patients who are within 10 days of the symptom onset and who have risk factors that leave them vulnerable to complications from the virus. For a complete list of qualifications for monoclonal antibody treatment, see our FAQs below. Insurance is accepted for this treatment.
What are monoclonal antibodies?
Monoclonal antibodies are produced in a laboratory. They serve as substitute antibodies that help our immune systems mimic the defense of natural COVID-19 antibodies. Innovative Care uses two types of monoclonal antibody treatment for COVID positive patients, Regen-COV and Bamlanivimab/etesevimab. These treatments have received FDA EUA approval. More information on Regen-COV and Bamlanivimab/etesevimab, can be found online.
What to Expect
Innovative COVID treats patients who qualify with monoclonal antibodies 5 days a week. Each visit begins with a physician consultation to discuss the treatment options. If the patient chooses to receive treatment, we will administer monoclonal antibodies during your visit. More information about what to expect can be found in the FAQs below.
Innovative COVID accepts most major insurance plans, and 90 percent of people who get this treatment will not get a bill or pay for monoclonal antibody treatment. Based on our experience, approximately five percent of patients will be required by their insurer to pay a co-pay (usually $40 or less). Another 5 percent will receive a bill for the medication infusion (usually about $350 after insurance). NOTE, if you do not have any medical insurance, your treatment will be covered under the federal CARES Act (no out of pocket cost to you).
Patients who are diagnosed with COVID-19 can also choose to have a monoclonal antibody treatment in the comfort of their own home. Our COVID Home Service is available to Chicago residents within 5 miles of our Lincoln Park location (1111 W Diversey).
1111 W DIVERSEY PKWY, CHICAGO IL 60614
136 OGDEN AVENUE, DOWNERS GROVE IL 60515
Monoclonal Antibody Treatment FAQ
Anyone age 12 and older who tested positive for COVID-19 (whether they are vaccinated or not), and has had COVID-19 symptoms for less than 10 days, and who has one of the following:
- Be at least 65 years old
- Have a BMI of more than 25 kg/m2, or if age 12-17, have BMI above the 85th percentile for their age and gender based on CDC growth charts
- Currently pregnant
- Have a medical condition, including:
- High blood pressure
- Chronic kidney disease
- Cardiovascular disease (including congenital heart disease, hypertension)
- Down syndrome
- Liver disease
- Chronic lung disease
- Sickle cell disease
- Immunosuppressive disease or immunosuppressive treatment
- Current or former smoker
- History of stroke or cerebrovascular disease
- Current or history of substance abuse
- Neurodevelopmental disorders or other conditions that confer medical complexity
- Have a medical-related technological dependence (e.g., tracheostomy, gastrostomy)
Note: Monoclonal antibody treatment needs to be given within 10 days of the start of symptoms.
Monoclonal antibodies are administered via an IV infusion at our clinics. The appointment lasts about 90 minutes and begins with an evaluation from our emergency medicine physician or provider. Patients who schedule an appointment are under no obligation to have the infusion. They come for a consultation, at which time they can make a decision about whether or not to get monoclonal antibodies. If they choose to undergo treatment, we will administer the treatment during the same appointment. Treatment is administered in a comfortable recliner. Following your infusion, you will need to stay on-site for one hour for monitoring.
After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19. When monoclonal antibodies attach to the spike protein, they can block the virus’s ability to enter cells — and slow down the infection.
In 2020, the FDA authorized several different monoclonal antibodies to treat COVID-19. More information can be found in this patient fact sheet.